

ESC Cardiovascular Round Table

CRT Workshop – 23 & 24 January 2020

“The Cancer Patient and Cardiology”

Biographies

- [Professor Giorgio MINOTTI, Italy](#)
- [Prof. J. H. Maduro, NL](#)
- [Prof. Thomas Suter, CH](#)
- [Dr Daniela Cardinale, IT](#)
- [Dr Juan Cardlos Plana Gomez, USA](#)
- [Dr Riccardo Asteggiano, IT](#)
- [Prof. Jose Luis Zamorano, ES](#)
- [Dr Torbjørn Omland, NO](#)
- [Dr Jessica Scott, USA](#)
- [Dr E.A.M. Feijen, NL](#)
- [Dr Teresa Lopez-Fernandez, ES](#)
- [Dr Javid Moslehi, USA](#)
- [Dr G. Owsianik, EU Commission](#)
- [Ms Antonella Cardone, ECPC, European Cancer Patient Coalition](#)
- [Prof. Lina Badimon, ES](#)



Giorgio MINOTTI

University Campus Bio-Medico of Rome, Italy

Giorgio Minotti is Professor of Pharmacology and Clinical Pharmacology at the University Campus Bio-Medico School of Medicine in Rome. He earned his degrees in Medicine and Oncology at the Catholic University School of Medicine in Rome. He was fellow of the Italian Association for Cancer Research, Fulbright Scholar and Fulbright Visiting Professor at the Departments of Biochemistry, Michigan State University, East Lansing, MI, and Physiology and Biophysics, Case Western Reserve University, Cleveland, OH.

He authored over 120 papers on pharmacokinetics, pharmacodynamics, and clinical correlates of cardiovascular toxicity from anticancer drugs. He edited books for Wiley and Sons Ltd. (Cardiovascular toxicity of non-cardiovascular drugs, 2010), and guest-edited special issues of Cell Biology and Toxicology (2006), Cardiovascular Toxicology (2007), Chemical Research in Toxicology (2008), Progress in Pediatric Cardiology (2014), Seminars in Oncology (2019). He is Editor-in-Chief of Chemotherapy, Deputy Editor of Cardio-Oncology, Editorial Board member of Journal of Pharmacology and Experimental Therapeutics. He is member of the Italian Societies of Pharmacology and Toxicology, member of the Research & Scientific Advisory Committee of International Cardio-Oncology Society.

His work has been awarded by Academic Press Inc., NATO Scientific Affairs Division, Southern Europe New Drugs Organization, Italian Association for Cancer Research, Italian National Council Research. He organized and chaired international meetings or workshops for the European Society of Toxicology (2005, 2007), the European Society of Cardiology (2008, 2017-2019), the Menarini International Foundation (2006, 2014, 2018).



John H. MADURO

University of Groningen, The Netherlands

John Maduro (50). Senior Radiation Oncologist, University Medical Center Groningen and Princess Maxima Center for Pediatric Oncology, The Netherlands. Finished training in radiation oncology in 2006. Fields of expertise pediatric oncology and breast cancer. Special interest in treatment related toxicity and proton therapy. Completed my PhD in medical science in 2009 at the University of Groningen.



Thomas SUTER

University Hospital Bern, Switzerland

Thomas Suter is board-certified in cardiology and internal medicine and the head of the Department of Internal Medicine at Lindenhofgruppe in Bern, Switzerland. In addition, he leads the Cardio-Oncology Service and is a member of the section for heart failure and cardiac transplantation at the University Hospital Bern. He received his medical degree from the University of Zurich and took residency training in internal medicine and cardiology at University Hospital Zürich, Boston University Medical Center and Brigham and Women's Hospital, Boston MA. During his cardiology training, he specialized on heart failure and cardiac transplantation. His clinical research during the past 20 years focused on the investigation of cardiovascular side effects of cancer therapeutics. He serves as the vice chair of the Council on Cardio-Oncology of the European Society of Cardiology and on several steering committees of multinational cancer trials. Furthermore, he is directing a basic research lab in which he investigates mechanisms of chemotherapeutic-associated cardiotoxicity. His publications include over 100 articles on heart failure, cancer drug-associated cardiovascular side effects and general cardiology.



Daniela CARDINALE

European Institute of Oncology, Milan, Italy

Since April 2009, she has been the head of the first Cardio oncology Unit in Italy, whose main areas of competence are:

- cardiac risk stratification in patients scheduled for oncologic treatment.
- prevention, early detection, monitoring, and treatment of cardiotoxicity.
- screening of cardiotoxicity in patients with cardiac disease.
- malignant pericardial effusion evaluation and intrapericardial treatment.

Head of the scientific research activities of the Cardiology Department at the European Institute of Oncology of Milan.

1. Main fields of scientific interest:

Cardiotoxicity caused by antitumor agents:

- Early diagnosis:

use of biochemical markers in the early identification of heart damage and in the stratification of cardiovascular risk after oncologic treatment.

evaluation of the potential cardiotoxicity of new chemotherapeutic drugs using biochemical markers and electrocardiographic monitoring.

evaluation of endothelial damage of antitumor agents.

- Prevention: use of cardioprotective drugs to prevent acute and chronic damage caused by antitumor agent.

- Treatment:

treatment strategies of cardiomyopathy induced by antitumor drugs.

2. Prevention and treatment of post-surgery atrial fibrillation

3. Intrapericardial therapy of malignant effusions

Speaker at national and international conferences. Teacher at courses and seminars of the Italian Association of Hospital Cardiologists, of the Italian Society of Cardiology, of the Cardiovascular Clinical Biochemistry Study Group, of the School of Specialization in Cardiology of the University of Milan, of the Institute of Clinical Physiology of the C.N.R., of the Italian Society of Cardiovascular Echocardiography, of the Italian Association of Medical Oncology, and of the Italian Society of Haematology.

Juan Carlos PLANA GOMEZ

Texas Heart Institute and Baylor St Luke's Medical Center, Houston, Texas, USA

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Baylor College of Medicine, Houston, TX	Clinical Residency	2000	Residency in Internal Medicine
Taylor College of Medicine, Houston, TX	Clinical Residency	2001	Chief Medical Resident in Internal Medicine
Baylor College of Medicine, Houston, TX	Clinical Fellowship	2004	Cardiovascular Disease Fellow, Level III Certification in Echocardiography, Level II Certification in Nuclear Cardiology

A. Personal Statement

Dr. Juan Carlos Plana is the Chief of Clinical Operations of the Section of Cardiology, Department of Medicine at Baylor College of Medicine. He is also the Chief of Cardiovascular Service Line at Baylor St. Luke's Medical Center. His area of expertise is echocardiography.

B. Positions and Honors

Professional Experience

- 1997 Instructor, Basic and Clinical Pharmacology, Universidad de la Sabana School of Medicine, Santafe de Bogota, Colombia.
- 2000 Clinical Instructor and Chief Medical Resident, Ben Taub General Hospital, Baylor College of Medicine, Houston, TX.
- 2001 Clinical Instructor and Chief Medical Resident, Department of Cardiology, The Methodist Hospital, Baylor College of Medicine, Houston, TX.
- 2006-2010 Director of Cardiac Imaging, Assistant Professor of Medicine, Department of Cardiology, Division of Internal Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
- 2010-2014 Co-Director Cardio-Oncology Center Section of Cardiovascular Imaging. Department of Cardiovascular Medicine. Cleveland Clinic. Cleveland, OH.
- 2014-present Chief of Clinical Operations at Baylor College of Medicine and Chief of Cardiovascular Service line at Baylor St. Luke's Medical Center, Houston, TX.

Honors



- 2000 Henry McIntosh award for the most outstanding resident in Internal Medicine.
- 2004 Best Clinical research award, Baylor College of Medicine, Section of Cardiology.
- 2007 Teacher of the year, Section of Cardiology, Department of Internal Medicine, The University of Texas Health Science Center.
- 2011 Distinguished Teacher of the year. Department of Cardiovascular Medicine. Cleveland Clinic.
- 2016 Inge Edler Gold Medal. Spanish Society of Cardiac Imaging, Madrid, Spain.



Riccardo ASTEGGIANO

LARC (Analysis Laboratory Clinical Research), Turin - Insubria University of Medicine – Varese, Italy

Riccardo Asteggiano graduated in Medicine and Surgery, and in 1983 he obtained the Specialty in Cardiology at the University of Turin. He has gained over 35 years of experience at ASL 2 and 3 Regione Piemonte with management of general cardiology clinic, Heart Failure patients' management programs, consultancy in hospital departments and was interested in Cardio-Oncology patients' management from the beginning of his activity. He is adjunct professor at the Faculty of Medicine of the Insubria University (Varese Italy). He is a member of the European Society of Cardiology, Past-Chair of the Council for Cardiology Practice and Chair of the Council of Cardio-Oncology of the ESC. He participated in the publication of numerous works including a Position Paper on Cardio-Oncology and was reviewer of some ESC Guidelines. He was a Faculty at the European Congress of Cardiology of the ESC from 2013 to 2019 and in many other national and international cardiology congresses.



[Jose Luis ZAMORANO](#)

University Hospital Ramón y Cajal, Madrid, Spain

Jose L. Zamorano is a Professor of Medicine at the University Alcala de Henares, Madrid, and the Chief of Cardiology at the University Hospital Ramón y Cajal. Prof. Zamorano obtained his medical degree from the University Complutense in 1987 and his doctor in Medicine in 1991. He received his board certification in Cardiology in 1993 before joining as an Associate Professor the faculty at the Complutense University.

Dr. Zamorano's has a broad range of research interests including heart failure, ischaemic heart disease, cardiovascular risk factors and cardiovascular imaging modalities. Within these fields, Prof. Zamorano has published over 400 articles and twenty books including the European Textbook of Cardiovascular Imaging. His impact factor is > 1500 and Hirsch Index of 100 with more than 15000 citations.

Prof. Zamorano has been actively participating in International Scientific Societies. Currently is Vicepresident of the European Society of Cardiology. He served as Secretary of the European Society of Cardiology (ESC), President of the European Association of Echocardiography (EAE), International Advisor of the American College of Cardiology's International Committee, director of the scientific programme in imaging for the ESC Congress, and member of the Practice Guidelines Committee of the ESC.

Over the past 20 years, Prof. Zamorano has received a number of prestigious Spanish and International awards, such as the Golden Plaque of the Public Health Authorities of Madrid and the Ingel Edler Gold Medal, the silver medal of the European Society of Cardiology and Research Award of the Spanish Society of Cardiology. He has served in different Editorial Boards of Research journals as the Spanish Journal of Cardiology, European Journal of echocardiography, European Journal of Cardiovascular Imaging, American Society of Echocardiography, European Heart Journal, Journal of American College of Cardiology Cardiovascular Imaging and International Relations Task Force of the American Society of Echocardiography. Currently is Associate Editor of the European Journal of Cardiovascular Imaging.



Torbjørn OMLAND

Professor of Medicine at the University of Oslo and Consultant Cardiologist at Akershus University Hospital, Oslo, Norway

Dr. Torbjørn Omland received his MD and PhD degrees from the University of Bergen, Norway. He has worked as a postdoctoral fellow at the Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School in Boston, and has also received a Master of Public Health degree from the Harvard School of Public Health.

Dr. Omland is Professor of Medicine at the University of Oslo, Norway, and is also Consultant Cardiologist at Akershus University Hospital. His research interests include cardiovascular biomarkers of subclinical myocardial injury and dysfunction, risk stratification of patients with heart failure and coronary artery disease, and prevention of cardiac injury and dysfunction in patients receiving cancer therapy. Dr Omland was the principal investigator of the ***PR*evention of *cA*rdiac *D*ysfunction during *A*djuvant breast cancer therapy (**PRADA**)** trial: a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol in early breast cancer patients receiving adjuvant therapy that included anthracyclines. Dr Omland is also the principal investigator of the ongoing multi-center trial PRADA II.

Dr. Omland has authored numerous scientific papers, review papers and book chapters concerning cardiovascular disease. These include articles in *Circulation*, *Journal of the American College of Cardiology*, *JAMA*, *The Lancet*, and *The New England Journal of Medicine*. He is co-editor of '*Chronic Coronary Artery Disease. A Companion to Braunwald's Heart Disease*', and is currently serving as an Associate Editor of *Circulation*.



[Jessica SCOTT](#)

Memorial Sloan Kettering Cancer Center, New York, US

Jessica Scott, PhD, is an Assistant Member in the Exercise Oncology Service at Memorial Sloan Kettering Cancer Center. She received her PhD in Exercise Cardiovascular Physiology at the University of British Columbia in Vancouver, Canada, and completed her Post-doctoral Fellowship at NASA Johnson Space Center (JSC) in Houston, Texas. She joined MSK in 2017 after 5 years as a Senior Scientist in the Exercise Physiology and Countermeasures Laboratory at JSC. Her research is focused on: (1) characterization of cancer treatment-related multisystem toxicity using exercise testing, imaging, and biomarker techniques, and (2) the efficacy of exercise training to prevent and/or reverse toxicity.



Lieke E.A.M. FEIJEN

Paediatric Oncology EKZ, Amsterdam, The Netherlands

1999-2004 Bsc Physical therapy

2006-2009 Msc Human movement science

2012-2015 PhD cardiotoxicity in childhood cancer survivors

Since 2018 working in the Princess Maxima Center for pediatric oncology. Senior researcher in a group of Prof. Leontien Kremer. Working on a large nationwide study Dutch LATER CARD, funded by the Dutch Heart association, about cardiotoxicity in childhood cancer survivors: echocardiography, ECG and blood biomarkers. The study is almost closing the inclusion, we have collected data on almost 1500 survivors and 300 siblings. 3 Phd-students are currently working on this project.



[Teresa LOPEZ-FERNANDEZ](#)

University Hospital La Paz, Madrid, Spain

Teresa López-Fernández is a clinical investigator and consultant cardiologist at La Paz University Hospital in Madrid, Spain. Dr López-Fernández specialises in cardiac imaging (she is board certified in advanced and transesophageal echocardiography by the European Society of Cardiology (ESC)) and cardio-oncology, and currently leads the cardiac imaging unit at La Paz University Hospital.

Dr López-Fernández set up and coordinates the cardio-oncology team at La Paz University Hospital. She is the founder and chair of the Spanish Cardio-Oncology Working Group at the Spanish Society of Cardiology (SEC). Dr López-Fernández is also regularly invited to speak about cardio-oncology at both national and international conferences.

Her current research interests focus on cardiotoxicity diagnosis and preventive strategies. Dr López-Fernández has authored over 100 peer-reviewed publications and book chapters.



Javid MOSLEHI

Vanderbilt University, Nashville, TN, US

Dr. Moslehi is an Associate Professor of Medicine at Vanderbilt School of Medicine. He directs the Cardio-Oncology program. Dr. Moslehi is also a physician-scientist whose laboratory focuses on myocyte biology and myocardial response to such stresses as hypoxia, cancer therapies including immunotherapies. Recently, he co-founded and co-directs the Vanderbilt Program for Optimizing Immuno-Oncology Therapy (V-POINT), a clinical and research group that brings a multi-disciplinary approach to the care of patients with immunotherapy associated toxicities. At Vanderbilt, he has established a Graduate Medical Education (GME) approved fellowship training the next generation of physician-scientists in the field of cardio-oncology.

Dr. Moslehi graduated from Johns Hopkins University and University of Connecticut School of Medicine. He completed internship and residency in internal medicine at Johns Hopkins Hospital followed by cardiovascular and vascular medicine fellowships at the Brigham and Women's Hospital and Harvard Medical School. He then completed a post-doctoral fellowship at the Dana-Farber Cancer Institute focusing on the role of angiogenesis in heart disease. In 2009, Dr. Moslehi joined the faculty at the Harvard Medical School and founded the Cardio-Oncology program at Brigham and Women's Hospital and Dana-Farber Cancer Institute. In 2014, he joined the faculty at Vanderbilt University School of Medicine.



Grzegorz OWSIANIK

European Commission, Brussels, DG Research & Innovation, Unit E2 - Combatting Diseases, Belgium

Grzegorz Owsianik graduated in Biology/Microbiology at the University of Wroclaw, Poland. He obtained his PhD. degree at the Université catholique de Louvain in Louvain-la-Neuve, Belgium for his work on the multidrug resistance. In 2002, he joined the electrophysiology group of Professor Bernd Nilius at the Katholieke Universiteit Leuven in Belgium. In 2014, he was appointed as a Programme and Policy Officer responsible for the cardiovascular research project portfolio at the DG Research and Innovation, European Commission in Brussels. Currently, he is a Team Leader for non-communicable diseases in the Unit E2 – Combatting diseases of the Commission.



[Antonella CARDONE](#)

European Cancer Patient Coalition, Brussels

Antonella Cardone is the Director of the European Cancer Patient Coalition. In that capacity she is Board Member of Pancreatic Cancer Europe and is chairing the Cancer-related complications and comorbidities Initiative. She has over twenty years of international activity in health, social and employment sectors. Prior to ECPC, Antonella was the Executive Director of the Fit for Work Global Alliance, a multi-stakeholder coalition championing change in health and work policy. She also worked with the European Multiple Sclerosis Platform, on the "Ready for Work" project. She was previously Director of the Global Smokefree Partnership of the American Cancer Society, leading a movement of over 100 members among civil society, universities, and ministries of health to coordinate the development of smoke-free laws in 40 countries. She holds a Master's in Business Administration.



Lina BADIMON

Cardiovascular Program (ICCC-IR), IIB-Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelone, Spain

Prof. Lina Badimon is the Director of the Cardiovascular Science Program (ICCC) at the Hospital Santa Creu and San Pau, Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona and Director of the UNESCO Chair in Biomedical Sciences Training and Research. She is the Chair of the Advocacy Committee and Board Member 2018-2020 of the European Society of Cardiology

Her research activities focus on cardio-metabolic diseases, thrombosis, atherosclerosis and ischemic heart disease. She has published over 590 articles in highly qualified scientific journals with her work highly quoted in the scientific literature (Citations: 49.864; hindex 78). She has written more of 250 reviews and book chapters.

She is Member of Editorial Boards of various international scientific journals. Previous appointments include: Fellow in Cardiovascular Diseases at The Mayo Clinic, Rochester, MN, USA (1981-1983); Director of the Cardiology Basic Research Laboratory of the Division of Cardiology at the Mount Sinai Medical Center, New York, NY (1983-1991); Assistant Professor of Medicine (1983-1987) and Associate Professor of Medicine (1988-1991) at the Mount Sinai School of Medicine, NY; Lecturer in Medicine at Harvard Medical School, Boston (1991-1994); Consultant at the Cardiac Unit, at the Massachusetts General Hospital, Boston (1991-1994)

Positions of Trust: Vice-President for Scientific Affairs of European Society of Cardiology (2016-2018), Vice President of the Spanish Society of Cardiology (2013-2015); Chairman of the Council on Basic Cardiovascular Science (2014-2016) and Chairman of the Working Group on Microcirculation (2012-2014) of the ESC; Past President of the European Society for Clinical Investigation (2000-2002) and Past President of the Spanish Society of Atherosclerosis (1996-2000); Member of the National Academy of Medicine and of the National Academy of Pharmacy of Catalonia and Spain.

Honorary Appointments: Fellow of the Cardiovascular Science Council and Fellow of the Atherosclerosis, Thrombosis and Vascular Biology Council of the American Heart Association; Fellow of the European Society of Cardiology; Distinguished Fellow of the International Atherosclerosis Society; Honorary Member of Spanish Society of Hypertension, of the Romanian Society of Hypertension, of Hungarian Society of Cardiology, of "Sociedad Peruana de Cardiología" and Spanish Society of Arteriosclerosis. She has received the "Narcís Monturiol" (1993) and "Creu de Sant Jordi" (2004) Medals from Generalitat de Catalunya; the "Rey Jaime I" Award – Medical Research (2014) from Generalitat Valenciana and named Doctor Honoris Causa by the Carol Davila University of Medicine and Pharmacy, Romania (2015).